Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Lotus Pharma Reports Higher Revenues, Lower Net

publication date: Aug 18, 2008
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Lotus Pharmaceuticals, Inc. released its Q2 financial report, which showed the company followed a theme similar to several other China biopharmas this quarter: revenues are sharply higher, but net income fails to keep pace. In fact, Lotus said its net income actually slipped lower than the year earlier period. In terms of actual numbers, Lotus’ revenues climbed a more-than-respectable 51% to $19.4 million, but profits were 27% lower at $2.2 million. Lotus blamed the shortfall on its sales costs, which climbed almost eight-fold. More details...

Stock Symbol: (OTCBB: LTUS)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...